<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841931</url>
  </required_header>
  <id_info>
    <org_study_id>11/09/VA05</org_study_id>
    <nct_id>NCT01841931</nct_id>
  </id_info>
  <brief_title>Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients</brief_title>
  <official_title>Buprenorphine Tx:A Safe Alternative for Opioid Dependent Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether buprenorphine can be at least as effective as
      other opioid medications in relieving chronic pain in patients who suffer from dependence on
      their opioid medications, while patients simultaneously experience progressive decline of
      pain along with absence of opioid withdrawal symptoms and improved quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will utilize sublingual buprenorphine for the treatment of chronic pain patients
      with co-occurring opioid dependence. Adult male and female chronic pain patients with
      co-occurring opioid dependence/disorder, being treated at MMC will be enrolled in a home
      induction procedure. Subjects will be switched from their current opioid pain medication to
      buprenorphine/naloxone to assess whether buprenorphine is at least as effective, if not more
      effective, as other opioid medications in controlling their pain while simultaneously
      improving their psychological distress, functional status, and other aspects of patients'
      lives. We will utilize a home induction procedure, and maintain subjects on this oral
      medication for a duration of 6 months. During this period
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator is no longer at this site
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opiate Withdrawal</measure>
    <time_frame>6 months</time_frame>
    <description>Goal that patients will have NO withdrawal symptoms by the completion of their 3-day buprenorphine induction, and will remain withdrawal-free for the entire study duration.Assessed using Clinical Opiate Withdrawal Scale (COWS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Severity</measure>
    <time_frame>6 months</time_frame>
    <description>Pain severity will be measured using a numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine), adopted from the Brief Pain Inventory (BPI).
No results to report.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric Distress</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators will utilize the SCL-6 (Symptoms Checklist 6, a validated abbreviated version of the SCL-90) to assess patients' psychological well being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Investigators will use the QOL (EuroQol EQ5D) questionnaire, which assess patients' self-assessment of health and health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Affect</measure>
    <time_frame>6 months</time_frame>
    <description>The investigators will assess patients' moods/affects using the PANAS (Positive Affect Negative Affect Scale).</description>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Opioid Use Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/Naloxone</intervention_name>
    <description>Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).</description>
    <other_name>Buprenorphine</other_name>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM criteria for opioid dependence (or opioid use disorder when DSM 5 is in use)

          -  Has received opioid therapy for at least 90 days

          -  Has opioid dependence as assessed by a Maimonides psychiatrist

        Exclusion Criteria:

          -  Scheduled for major surgery during study duration

          -  Predicted life expectancy &lt; 1 year

          -  Plan to cease habitation in greater New York area within 6 months

          -  Risks for buprenorphine outweigh potential benefit, as determined by the PI

          -  Lacks sufficient fluency in English to understand the study protocol, answer survey
             questions or give informed consent

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Kolodny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center Dept. of Psychiatry Chairman</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.britishpainsociety.org/book_opioid_main.pdf</url>
    <description>British Pain Society guidelines on prescribing opioids, intended for both doctors and patients.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628995/bin/11606_2008_866_MOESM1_ESM.pdf</url>
    <description>direct link to PDF of home induction packet used in study (NYU school of medicine version from study by Lee et. al.)</description>
  </link>
  <reference>
    <citation>TEDS. Treatment Episode Data Set, 1998-2008. Subsance Abuse and Mental Health Services Administration, Office of Applied Studies, http://wwwdasis.samhsa.gov/webt/NewMapv1.htm</citation>
  </reference>
  <reference>
    <citation>EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.</citation>
    <PMID>10109801</PMID>
  </reference>
  <reference>
    <citation>Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994 May;55(5):569-80.</citation>
    <PMID>8181201</PMID>
  </reference>
  <reference>
    <citation>Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70.</citation>
    <PMID>3397865</PMID>
  </reference>
  <reference>
    <citation>Rosen CS, Drescher KD, Moos RH, Finney JW, Murphy RT, Gusman F. Six- and ten-item indexes of psychological distress based on the Symptom Checklist-90. Assessment. 2000 Jun;7(2):103-11.</citation>
    <PMID>10868247</PMID>
  </reference>
  <reference>
    <citation>Sobell, L.C., &amp; Sobell, M.B., Alcohol Timeline Followback (TFLB), in Handbook or Psychiatric Measures, I.A.P.A. (ed.), Editor. 2000, American Psychiatric Association: Washington, D.C. p. 477-479.</citation>
  </reference>
  <reference>
    <citation>Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009 Feb;24(2):226-32. doi: 10.1007/s11606-008-0866-8. Epub 2008 Dec 17.</citation>
    <PMID>19089508</PMID>
  </reference>
  <reference>
    <citation>Schilthuizen M, Stouthamer R. Horizontal transmission of parthenogenesis-inducing microbes in Trichogramma wasps. Proc Biol Sci. 1997 Mar 22;264(1380):361-6.</citation>
    <PMID>9107051</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <results_first_submitted>March 23, 2018</results_first_submitted>
  <results_first_submitted_qc>March 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2018</results_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioids</keyword>
  <keyword>Dependence</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patient</title>
          <description>Enrolled patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">As the PI left the institution the study was terminated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Chronic pain patients with opioid dependence</population>
      <group_list>
        <group group_id="B1">
          <title>Patient</title>
          <description>Enrolled patients</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain severity</title>
          <description>Pain Severity measured with a numeric scale (0 to 10) - Brief Pain Inventory (BPI)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opiate Withdrawal</title>
        <description>Goal that patients will have NO withdrawal symptoms by the completion of their 3-day buprenorphine induction, and will remain withdrawal-free for the entire study duration.Assessed using Clinical Opiate Withdrawal Scale (COWS).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient</title>
            <description>Enrolled patients</description>
          </group>
        </group_list>
        <measure>
          <title>Opiate Withdrawal</title>
          <description>Goal that patients will have NO withdrawal symptoms by the completion of their 3-day buprenorphine induction, and will remain withdrawal-free for the entire study duration.Assessed using Clinical Opiate Withdrawal Scale (COWS).</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Severity</title>
        <description>Pain severity will be measured using a numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine), adopted from the Brief Pain Inventory (BPI).
No results to report.</description>
        <time_frame>6 months</time_frame>
        <population>Enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Patient</title>
            <description>Enrolled patients</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Severity</title>
          <description>Pain severity will be measured using a numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine), adopted from the Brief Pain Inventory (BPI).
No results to report.</description>
          <population>Enrolled patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychiatric Distress</title>
        <description>The investigators will utilize the SCL-6 (Symptoms Checklist 6, a validated abbreviated version of the SCL-90) to assess patients' psychological well being.</description>
        <time_frame>6 months</time_frame>
        <population>Enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Patient</title>
            <description>Enrolled patients</description>
          </group>
        </group_list>
        <measure>
          <title>Psychiatric Distress</title>
          <description>The investigators will utilize the SCL-6 (Symptoms Checklist 6, a validated abbreviated version of the SCL-90) to assess patients' psychological well being.</description>
          <population>Enrolled patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Investigators will use the QOL (EuroQol EQ5D) questionnaire, which assess patients' self-assessment of health and health-related quality of life.</description>
        <time_frame>6 months</time_frame>
        <population>Enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Patient</title>
            <description>Enrolled patients</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Investigators will use the QOL (EuroQol EQ5D) questionnaire, which assess patients' self-assessment of health and health-related quality of life.</description>
          <population>Enrolled patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Affect</title>
        <description>The investigators will assess patients' moods/affects using the PANAS (Positive Affect Negative Affect Scale).</description>
        <time_frame>6 months</time_frame>
        <population>Enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Patient</title>
            <description>Enrolled patients</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Affect</title>
          <description>The investigators will assess patients' moods/affects using the PANAS (Positive Affect Negative Affect Scale).</description>
          <population>Enrolled patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Patient</title>
          <description>Enrolled patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was prematurely terminated as the PI left the institution.
Early termination lead to small numbers of subject enrollment and only baseline data. No data collection at 6 months or thereafter.
No adverse events.
No results to report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Research, Department of Psychiatry</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-7162</phone>
      <email>tjacob@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

